Table 3.
Characteristics of the PLCRC participants at diagnosis (2013–Aug’19), compared with the general Dutch CRC population (2013–’17), stratified by tumor stage.
| Baseline characteristics | Dutch population with CRC between 2013- ‘17 Stage I (n = 17,686) | PLCRC participants 2013-Aug’19 Stage I (n = 849) | Standardized difference (d)a | Dutch population with CRC between 2013- ‘17 Stage II (n = 17,951) | PLCRC participants 2013-Aug’19 Stage II (n = 1063) | Standardized difference (d)a | Dutch population with CRC between 2013- ‘17 Stage III (n = 21,707) | PLCRC participants 2013-Aug’19 Stage III (n = 1929) | Standardized difference (d)a | Dutch population with CRC between 2013- ‘17 Stage IV (n = 15,341) | PLCRC participants 2013-Aug’19 Stage IV (n = 918) | Standardized Difference (d)a |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age at diagnosis | 69.3 ± 9.1 | 66.8 ± 9.0 | 0.28 | 71.2 ± 10.6 | 66.9 ± 10.4 | 0.41 | 68.4 ± 11.2 | 64.2 ± 10.6 | 0.38 | 68.4 ± 11.8 | 62.2 ± 11.0 | 0.55 |
| < 55 years | 910 (5%) | 64 (8%) | 1205 (7%) | 123 (12%) | 2440 (11%) | 326 (17%) | 1921 (13%) | 220 (24%) | ||||
| 55–64 years | 3.861 (22%) | 258 (30%) | 3117 (17%) | 302 (28%) | 4929 (23%) | 607 (31%) | 3341 (22%) | 303 (33%) | ||||
| 65–74 years | 7.486 (42%) | 367 (43%) | 6362 (35%) | 385 (36%) | 7656 (35%) | 689 (36%) | 5098 (33%) | 281 (31%) | ||||
| 75–84 years | 4.674 (26%) | 143 (17%) | 5612 (31%) | 211 (20%) | 5341 (25%) | 273 (14%) | 3855 (25%) | 102 (11%) | ||||
| ≥ 85 years | 755 (4%) | 17 (2%) | 1655 (9%) | 42 (4%) | 1341 (6%) | 34 (2%) | 1126 (7%) | 12 (1%) | ||||
| Sex | 0.08 | 0.19 | 0.08 | 0.11 | ||||||||
| Male | 10,411 (59%) | 531 (63%) | 9695 (54%) | 675 (64%) | 12,340 (57%) | 1176 (61%) | 8669 (57%) | 567 (62%) | ||||
| Female | 7275 (41%) | 318 (37%) | 8256 (46%) | 388 (36%) | 9367 (43%) | 753 (39%) | 6672 (43%) | 351 (38%) | ||||
| BMI at diagnosisb (kg/m2) | 27.2 ± 4.6 | 27.2 ± 4.8 | 0.01 | 26.5 ± 4.7 | 26.9 ± 5.0 | 0.08 | 26.6 ± 4.6 | 26.3 ± 4.4 | 0.08 | 25.6 ± 4.4 | 25.9 ± 5.7 | 0.06 |
| Underweight (< 18.5) | 28 (1%) | 1 (0%) | 72 (2%) | 4 (1%) | 62 (1%) | 5 (1%) | 66 (3%) | 0 (0%) | ||||
| Normal weight (18.5–24.9) | 1134 (32%) | 119 (40%) | 1323 (39%) | 103 (35%) | 1606 (37%) | 216 (42%) | 1189 (46%) | 64 (50%) | ||||
| Overweight (25–29.9) | 1532 (44%) | 112 (37%) | 1367 (40%) | 129 (43%) | 1774 (41%) | 214 (41%) | 952 (37%) | 48 (37%) | ||||
| Obese (≥ 30) | 798 (23%) | 68 (23%) | 668 (19%) | 61 (21%) | 855 (20%) | 83 (16%) | 370 (14%) | 17 (13%) | ||||
| Primary tumor localizationc | 0.14 | 0.25 | 0.24 | 0.23 | ||||||||
| Rectum (C19.9, C20.9) | 5543 (31%) | 321 (38%) | 3836 (21%) | 342 (32%) | 8813 (41%) | 1008 (52%) | 4234 (28%) | 354 (39%) | ||||
| Colon (C18.0–18.7) | 12,143 (69%) | 528 (62%) | 14,115 (79%) | 721 (68%) | 12,894 (59%) | 921 (48%) | 11,107 (72%) | 564 (61%) | ||||
| Right colon (C18.0–18.4) | 4686 (39%) | 253 (48%) | 7757 (55%) | 406 (56%) | 6314 (49%) | 425 (46%) | 5487 (49%) | 246 (44%) | ||||
| Left colon (C18.5–18.7) | 7245 (60%) | 269 (51%) | 6040 (43%) | 304 (42%) | 6326 (49%) | 481 (52%) | 5023 (45%) | 305 (54%) | ||||
| Colon unspecified (C18.8–18.9) | 212 (2%) | 6 (1%) | 318 (2%) | 11 (2%) | 254 (2%) | 15 (2%) | 597 (5%) | 13 (2%) |
aStandardized differences (d) are differences in means or proportions divided by standard error; d > 0.20 indicate a large difference, d 0.10–0.20 indicate a small difference, and d < 0.10 indicate a negligible difference17,18.
bBMI at diagnosis for PLCRC only available when participants were enrolled at diagnosis and provided PROs (n = 1244); the NCR only collected height and weight in 2015, thus the reference values for BMI originate only from patients diagnosed in 2015 (n = 13,796).
cStandardized differences calculated over the proportion rectum versus colon tumors.